Urokinase clears blot clots in stroke patients
Swiss surgeons have significantly improved mechanical removal of blood clots in stroke patients by intra-arterial administration of the thromolytic urokinase.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1165 entries already.
Entries by Thomas Gabrielczyk
Sanofi buys Synthorx Inc for US$2.35bn
/in News/by Thomas GabrielczykSanofi will acquire Synthorx Inc to expand its immuno-oncology pipeline with THOR-707, an optimised IL-2 candidate.
Meatable NV raises US$10m in seed funding
/in News/by Thomas GabrielczykMeatable NV, a specialist for cultivated meat, has raised an additional US$10m in seed funding, bringing the companys total funding to US$13m.
Big Pharma is cost driver of GAVI
/in News/by Thomas GabrielczykMédecins Sans Frontières (MSF) called on the GAVI Vaccine Alliance not to pay huge subsidies to Big Pharma companies for pneumococcal vaccine
ImCheck Therapeutics SAS raises 48m
/in News/by Thomas GabrielczykT cell agonist specialist ImCheck Therapeutics will use 48m (US$53m) from a Series B financing to push clincial pipeline of antibodies activating gamma-delta T-cells.
Pierre Fabre amends license agreement with Puma Biotechnology
/in News/by Thomas GabrielczykPierre Fabre SA and Puma Biotechnology, Inc. have broadened the geographic coverage of their license agreement on commercialisation of Nerlynx® (neratinib).
European circular bioeconomy fund near closing
/in News/by Thomas GabrielczykThe European Commission and the European Investment Bank (EIB) have selected ECBF Management GmbH as investment advisor for the 250m EU circular bioeconomy fund.
Researchers find new indication for cancer drug
/in News/by Thomas GabrielczykFrench researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
Research team improves safety of LGMD2A gene therapy
/in News/by Thomas GabrielczykResearchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
GeNeuro and Karolinska Institute collaborate in multiple sclerosis
/in News/by Thomas GabrielczykGeneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.